» Articles » PMID: 12966419

Performance Status Score: Do Patients and Their Oncologists Agree?

Overview
Journal Br J Cancer
Specialty Oncology
Date 2003 Sep 11
PMID 12966419
Citations 83
Authors
Affiliations
Soon will be listed here.
Abstract

Oncologists traditionally assess their patients' ECOG performance status (PS), and few studies have evaluated the accuracy of these assessments. In this study, 101 patients attending a rapid access clinic at Papworth Hospital with a diagnosis of lung cancer were asked to assess their own ECOG PS score on a scale between 0 and 4. Patients' scores were compared to the PS assessment of them made by their oncologists. Of 98 patients with primary non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC), weighted kappa statistics showed PS score agreement between patient and oncologist of 0.45. Both patient- and oncologist-assessed scores reflected survival duration (in NSCLC and SCLC) as well as disease stage (in NSCLC), with oncologist-assessed scores being only marginally more predictive of survival. There was no sex difference in patient assessment of PS scores, but oncologists scored female patients more pessimistically than males. This study showed that, with few exceptions, patients and oncologists assessed PS scores similarly. Although oncologists should continue to score PS objectively, it may benefit their clinical practice to involve their patients in these assessments.

Citing Articles

Smartphone-based measures as real-world indicators of functional status in advanced cancer patients.

Straczkiewicz M, Keating N, Schonholz S, Matulonis U, Horowitz N, Campos S medRxiv. 2025; .

PMID: 39974129 PMC: 11838621. DOI: 10.1101/2025.02.04.25321686.


A new prognostic model for predicting overall survival and progression-free survival in unresectable hepatocellular carcinoma treated with the FOLFOX-HAIC regimen based on patient clinical characteristics and blood biomarkers.

Zeng Q, Zhou Z, Zhang J, Cai R, Yang H, Chen P BMC Cancer. 2025; 25(1):112.

PMID: 39838301 PMC: 11752828. DOI: 10.1186/s12885-024-13390-4.


Incidence and determinants of mortality among patients with colorectal cancer in oncology centers of Amhara region, Ethiopia, 2024: multicenter retrospective follow up study.

Walle G, Kitaw T, Adane S BMC Cancer. 2025; 25(1):102.

PMID: 39827340 PMC: 11742809. DOI: 10.1186/s12885-025-13462-z.


Patient-reported performance status and postoperative complications in elective colorectal cancer surgery.

Pardes H, Dohrn N, Dolin T, Gogenur I, Klein M Int J Colorectal Dis. 2024; 39(1):187.

PMID: 39567406 PMC: 11579060. DOI: 10.1007/s00384-024-04761-1.


Acute kidney injury in hematological patients treated with CAR-T cells: risk factors, clinical presentation and impact on outcomes.

Russo E, Gambella M, Raiola A, Beltrametti E, Zanetti V, Chirco G Sci Rep. 2024; 14(1):26886.

PMID: 39506012 PMC: 11542077. DOI: 10.1038/s41598-024-77720-z.


References
1.
Firat S, Byhardt R, Gore E . Comorbidity and Karnofksy performance score are independent prognostic factors in stage III non-small-cell lung cancer: an institutional analysis of patients treated on four RTOG studies. Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys. 2002; 54(2):357-64. DOI: 10.1016/s0360-3016(02)02939-5. View

2.
Stommel M, Given B, Given C . Depression and functional status as predictors of death among cancer patients. Cancer. 2002; 94(10):2719-27. DOI: 10.1002/cncr.10533. View

3.
Oken M, Creech R, Tormey D, Horton J, Davis T, McFadden E . Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982; 5(6):649-55. View

4.
Roila F, Lupattelli M, Sassi M, Basurto C, Bracarda S, Picciafuoco M . Intra and interobserver variability in cancer patients' performance status assessed according to Karnofsky and ECOG scales. Ann Oncol. 1991; 2(6):437-9. DOI: 10.1093/oxfordjournals.annonc.a057981. View

5.
Sengelov L, Kamby C, Geertsen P, Andersen L, von der Maase H . Predictive factors of response to cisplatin-based chemotherapy and the relation of response to survival in patients with metastatic urothelial cancer. Cancer Chemother Pharmacol. 2000; 46(5):357-64. DOI: 10.1007/s002800000176. View